Scinai Immunotherapeutics Ltd. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
SCNI Nasdaq 2830 www.scinai.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Scinai Immunotherapeutics Ltd.

Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility - May 20th, 2026 5:00 am
Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe - May 15th, 2026 5:30 am
Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing - Apr 24th, 2026 6:00 am
Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities - Apr 6th, 2026 5:00 am
Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration - Apr 1st, 2026 5:00 am
Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026 - Mar 19th, 2026 5:50 am
Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price - Mar 16th, 2026 2:05 pm
Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept - Mar 2nd, 2026 7:20 am
Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform - Feb 25th, 2026 6:11 am
Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm - Feb 17th, 2026 5:00 am
Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL - Jan 7th, 2026 5:00 am
Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances - Dec 2nd, 2025 6:50 am
Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities - Oct 6th, 2025 5:30 am
Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet - Sep 2nd, 2025 5:30 am
Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN - Jul 29th, 2025 5:15 am
Scinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology" - Jun 26th, 2025 5:30 am
Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025 - Jun 12th, 2025 6:00 am